Reader Question :
Leave G9143 to Testing Entity
Published on Fri Feb 26, 2010
Question: When should I use the new testing code for warfarin (G9143)?Wisconsin SubscriberAnswer: You should report G9143 (Warfarin responsiveness testing by genetic technique using any method, any number of specimen[s]) only if you're reporting the actual testing to see how a patient's genetic makeup affects the body's response to warfarin, also called pharmacogenomic testing. So a lab is likely to report this code.Background: As of Aug. 3, 2009, Medicare covers pharmacogenomic testing to predict warfarin responsiveness only "in the context of a prospective randomized, controlled clinical study when that study meets certain criteria as outlined in the Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Section 90.1," states MLN Matters article MM6715 (
www.cms.hhs.gov/MLNMattersArticles/downloads/MM6715.pdf).According to the article, testing is covered if the beneficiary meets three conditions:1. Is a candidate for anticoagulation therapy with warfarin2. Has not been previously tested for CYP2C9 or VKORC1 alleles (the alleles warfarin responsiveness is limited [...]